JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - XERIS BIOPHARMA HOLDINGS INC
Financial Performance:
- Raised full-year revenue guidance to $395–$405 million, representing 37% growth at the midpoint.
- Third-quarter Recorlev sales reached approximately $71 million, driving an accelerated growth trajectory.
- Maintained profitability with gross margins of 88% and improving quarterly trends.
- No specific cash balance or debt figures provided; management confirmed strong balance sheet capacity.
Guidance and Future Outlook:
- Raised 2030 revenue outlook from $750 million to over $1 billion, driven by three core products and new development.
- Anticipates Recorlev reaching $1 billion in peak sales within 3–4 years, accelerated from the previous 2035 target.
- Projecting significant growth in 2024 with Recorlev, G-Voke (9–10% growth), and Caveas returning to growth.
- Phase 3 program for product 8121 (hypothyroidism) to initiate by end of year, with top-line data targeted for late 2028 and approval expected in 2030.
Business Segments and Product Lines:
- Recorlev (Cushing's): Growth engine; doubled sales force in January; benefiting from guideline updates (ADA, ESAD) encouraging screening for resistant diabetes/hypertension; >60% of new patients are treatment-naïve.
- G-Voke (Hypoglycemia): Returning to growth mode; addressing the gap in the 15 million eligible diabetic population where <1 million currently use ready-to-use glucagon.
- Caveas (Primary Periodic Paralysis): Ultra-rare product; recent field investments made to restart growth trajectory in the 4,000–5,000 patient pool.
- 8121 (Hypothyroidism): Once-weekly subcutaneous levothyroxine alternative for 3–5 million patients with absorption issues; non-inferiority "Cornerstone" trial designed for FDA approval.
Market and Competitive Landscape:
- Market trends show increased clinical screening for hypercortisolism in primary care settings due to updated guidelines.
- Recorlev is expanding prescriber base from specialists to primary care physicians (PCPs).
- Hypothyroidism market lacks innovation in 40 years; 25% of analyzed patients were out of biochemical range on consecutive tests.
- No immediate evidence of payer restrictions (e.g., prior authorization hurdles) on Recorlev, as the rare disease category and medical necessity criteria limit payer leverage.
Risks and Challenges:
- Patient persistence risks in the first 3–4 months post-t initiation due to cortisol withdrawal symptoms and the need to adjust comorbid medications.
- G-Voke faces challenges in changing physician practice habits regarding glucagon prescription protocols.
- Caveas requires significant patient education and identification efforts in a very small population.
- 8121 relies on demonstrating non-inferiority; while superiority is a target, the primary path to approval is non-inferiority.
Management Commentary and Tone:
- Tone was highly confident and optimistic, citing "record" growth and new trajectories across all three commercial products.
- Management emphasized the successful acceleration of Recorlev's sales force expansion and the alignment with clinical guidelines.
- Expressed discipline regarding M&A/Business Development, prioritizing assets that drive revenue within 3–6 years to complement the 8121 pipeline.
Analyst Questions and Answers:
- Q: Recorlev persistence and switching? A: Majority are new starts; persistence is stable after the initial 3–4 month adjustment period.
- Q: Access restrictions/payer pushback? A: Minimal current restrictions due to prior authorization requirements and the high unmet medical need; payers have limited ability to deny based on cost in rare disease.
- Q: 2027 revenue bookends? A: Recorlev annualized at Q3 run rate plus growth in G-Voke and Caveas suggests a robust growth year; implied 2027 Recorlev run rate could approach $350M.
- Q: 8121 trial design? A: "Cornerstone" trial is a non-inferiority study vs. oral levothyroxine (Synthroid) in 500 patients; additional pillars include special population conversion study and real-world evidence generation.
Other Key Points:
- Recorlev sales force expansion in January was the third major expansion since the 2022 launch.
- G-Voke prescription data indicates the market is growing, and Xeris is capturing a share greater than fair market share.
- Xeris plans to use existing clinical data (failure on oral levothyroxine) to streamline prior authorization for 8121, avoiding the need to initiate new therapies for patients already on treatment.
- 8121 peak sales are projected between $1 billion and $3 billion, targeting only 10% of the 3–5 million eligible patients.
- Company
- XERIS BIOPHARMA HOLDINGS INC
- Keywords
- XERIS BIOPHARMA HOLDINGS INC